Institutional members access full text with Ovid®

Acute and Impaired Wound Healing: Pathophysiology and Current Methods for Drug Delivery, Part 1: Normal and Chronic Wounds: Biology, Causes, and Approaches to Care

Demidova-Rice, Tatiana N. PhD; Hamblin, Michael R. PhD; Herman, Ira M. PhD

Advances in Skin & Wound Care: July 2012 - Volume 25 - Issue 7 - p 304–314
doi: 10.1097/01.ASW.0000416006.55218.d0
Features: Original Investigations

ABSTRACT: This is the first installment of 2 articles that discuss the biology and pathophysiology of wound healing, review the role that growth factors play in this process, and describe current ways of growth factor delivery into the wound bed. Part 1 discusses the latest advances in clinicians’ understanding of the control points that regulate wound healing. Importantly, biological similarities and differences between acute and chronic wounds are considered, including the signaling pathways that initiate cellular and tissue responses after injury, which may be impeded during chronic wound healing.

In part 1 of this article series, the authors discuss the biology and pathophysiology of wound healing, review the role that growth factors play in this process, and describe current ways of growth factor delivery into the wound bed.

Tatiana N. Demidova-Rice, PhD, is a post-doctoral fellow at E.L. Steele Laboratory of Tumor Biology, Massachusetts General Hospital, Boston, Massachusetts.

Michael R. Hamblin, PhD, is Associate Professor, Department of Dermatology and Principal Investigator, Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts.

Ira M. Herman, PhD, is Professor and Director, Program in Cellular and Molecular Physiology, Sackler School of Graduate Biomedical Sciences and The Center for Innovations in Wound Healing Research, and Tufts University School of Medicine, Boston, Massachusetts.

Drs Demidova-Rice and Hamblin have disclosed they have no financial relationships related to this article.

Dr Herman has disclosed that he is/was a recipient of grant/research funding from the National Institutes of Health and Wound Care Partners, LLC; is/was a consultant/advisor to Healthpoint Biotherapeutics, Inc, and Nell One, Inc; was a consultant/advisor to Healthpro Bioventures and Amach Partners; and is a stock shareholder in Wound Care Partners, LLC.

Correspondence may be sent to Dr Herman at ira.herman@tufts.edu.

Submitted January 27, 2011; accepted in revised version June 8, 2011.

© 2012 Lippincott Williams & Wilkins, Inc.